NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
12 Jan 2012

AM-Pharma Announces Appointment of Russell Greig as Chairman.

Bunnik, The Netherlands, 4 January 2012. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and Inflammatory bowel diseases, today announced the appointment of Dr Russell Greig as Chairman of the Supervisory Board.
12 Jan 2012

Endosense launches TactiCath 75 force-sensing catheter, announces new results of EFFICAS clinical study.

GENEVA – January 12, 2011 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced the European launch of the TactiCath 75 force-sensing ablation catheter as well as results of the EFFICAS clinical study of contact force-sensing in catheter ablation procedures.
09 Jan 2012

TiGenix Reports Positive Results of ChondroCelect. Compassionate Use Program.

Leuven (BELGIUM) – January 9, 2011 – TiGenix (NYSE Euronext: TIG), a leading biopharmaceutical company that commercializes and develops cell therapies, today announced data from a ChondroCelect® compassionate use program (CUP), involving 43 orthopedic centers in 7 European countries, treating 370 patients with ChondroCelect over the span of four years.
01 Dec 2011

Ysios Capital Partners and “la Caixa” lead MedLumics €3.5million/$4.7million Series A Financing.

MADRID - December 1, 2011 – MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the closing of a 3.5 million Euro/4.7 million USD Series A financing.
01 Dec 2011

Ysios Capital Partners and “la Caixa” lead MedLumics €3.5million/$4.7million Series A Financing.

MADRID - December 1, 2011 – MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the closing of a 3.5 million Euro/4.7 million USD Series A financing.
Ysios Capital Partners leads €29.2million Series D Financing of AM-Pharma<
13 Sep 2011

Ysios Capital Partners leads €29.2million Series D Financing of AM-Pharma

The oversubscribed series D round was led by Ysios Capital Partners, co-led by Kurma Life Science Partners.
13 Sep 2011

Ysios Capital Partners leads €29.2million Series D Financing of AM-Pharma

Barcelona, Spain, 13 September 2011 – Ysios Capital Partners, the Spanish life sciences venture capital firm, today announces that is has led the €29.2 million Series D financing of AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) as a treatment of severe inflammatory diseases.
15 Jun 2011

Ysios Capital Partners leads €2million series A financing of STAT Diagnostica

Barcelona 15th June 2011 - Ysios Capital Partners today announces that it has led a €2M Series A investment in STAT Diagnostica, a company based in the Barcelona Science Park.
24 Jan 2011

Amgen to acquire Biovex for up to $1 bn

THOUSAND OAKS, Calif., and WOBURN, Mass. (Jan. 24, 2011) – Amgen (NASDAQ: AMGN) and BioVex Group, Inc. today announced that the companies have entered into a definitive acquisition agreement under which Amgen has agreed to acquire BioVex Group, Inc., a privately held, venture-funded, biotechnology company headquartered in Woburn, Mass. BioVex is developing OncoVEXGM-CSF, a novel oncolytic vaccine in Phase 3 clinical development, that may represent a new approach to treating melanoma and head and neck cancer.
21 Sep 2010

Ysios Capital Partners leads €5million Series A Financing of Sabirmedical

Ysios Capital Partners leads € 5 Million

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка